Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 16


Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.

Han S, Kim YJ, Lee J, Jeon S, Hong T, Park GJ, Yoon JH, Yahng SA, Shin SH, Lee SE, Eom KS, Kim HJ, Min CK, Lee S, Yim DS.

J Hematol Oncol. 2015 Oct 23;8(1):118. doi: 10.1186/s13045-015-0208-3.


Spotlight on decitabine for myelodysplastic syndromes in Chinese patients.

Jing Y, Shen X, Mei Q, Han W.

Onco Targets Ther. 2015 Oct 3;8:2783-90. doi: 10.2147/OTT.S81093. eCollection 2015. Review.


Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.

Kang H, Wang X, Gao L, Cen J, Li M, Wang W, Wang N, Li Y, Wang L, Yu L.

Eur J Med Res. 2015 Feb 20;20:16. doi: 10.1186/s40001-015-0092-x.


HOXA11 gene is hypermethylation and aberrant expression in gastric cancer.

Bai Y, Fang N, Gu T, Kang Y, Wu J, Yang D, Zhang H, Suo Z, Ji S.

Cancer Cell Int. 2014 Aug 19;14:79. doi: 10.1186/s12935-014-0079-7. eCollection 2014.


Human factors and pathways essential for mediating epigenetic gene silencing.

Poleshko A, Kossenkov AV, Shalginskikh N, Pecherskaya A, Einarson MB, Marie Skalka A, Katz RA.

Epigenetics. 2014 Sep;9(9):1280-9. doi: 10.4161/epi.32088. Epub 2014 Aug 4.


Clinical impact of recent genetic discoveries in osteoporosis.

Mitchell BD, Streeten EA.

Appl Clin Genet. 2013 Oct 4;6:75-85. doi: 10.2147/TACG.S52047. Review.


Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.

Ricketts CJ, Morris MR, Gentle D, Shuib S, Brown M, Clarke N, Wei W, Nathan P, Latif F, Maher ER.

Clin Epigenetics. 2013 Sep 13;5(1):16. doi: 10.1186/1868-7083-5-16.


Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.

Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S289-94. doi: 10.1016/j.clml.2013.05.025. Epub 2013 Aug 19.


p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Chen L, Tweddle DA.

Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.


Do epigenetic marks govern bone mass and homeostasis?

Delgado-Calle J, Garmilla P, Riancho JA.

Curr Genomics. 2012 May;13(3):252-63. doi: 10.2174/138920212800543129.


Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax.

Bracht JR, Perlman DH, Landweber LF.

Genome Biol. 2012 Oct 17;13(10):R99. doi: 10.1186/gb-2012-13-10-r99.


Advances in haematological pharmacotherapy in 21st century.

Ghosh K, Ghosh K.

Indian J Hematol Blood Transfus. 2010 Jun;26(2):30-40. doi: 10.1007/s12288-010-0019-1. Epub 2010 Sep 28.


Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.

Cancer. 2011 Oct 1;117(19):4424-38. doi: 10.1002/cncr.26073.


DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.

Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK.

J Natl Cancer Inst. 2011 Jan 19;103(2):143-53. doi: 10.1093/jnci/djq497. Epub 2010 Dec 16.


Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.

Eberth S, Schneider B, Rosenwald A, Hartmann EM, Romani J, Zaborski M, Siebert R, Drexler HG, Quentmeier H.

BMC Cancer. 2010 Sep 29;10:517. doi: 10.1186/1471-2407-10-517.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk